Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27625281 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2FPR2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28364110 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2FPR2KDM4EMAPTKMT2A | |
| Bromide SCHEMBL28364106 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2FPR2KDM4EMAPTKMT2A | |
| SCHEMBL29247131 | 0.73 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL1353073 | 0.72 | ALPG (0.41) | KDM4EMAPTKMT2A | |
| SCHEMBL23409262 | 0.71 | KDM4E (0.47) | SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL14148932 | 0.71 | L3MBTL1 (0.46) | SMN1; SMN2KDM4EL3MBTL1MAPTKMT2A | |
| Ethane SCHEMBL27625282 | 0.70 | ALPG (0.40) | KDM4EMAPTKMT2A | |
| SCHEMBL28525336 | 0.70 | KMT2A (0.39) | SMN1; SMN2FPR2KDM4EKMT2A | |
| SCHEMBL298299 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2389366-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8040502-B2 | Optical inspection of flat media using direct image technology | WDI WISE DEVICE INC. (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | disclosed |
| EP-2358735-A1 | AZEPINONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010084979-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212891-A1 | AZEPINONE DERIVATIVES | AZI2, NDUFS3, RPS4Y1 | SMN1; SMN2 4372/4885FPR2 3671/4885KDM4E 530/4885 |
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | DGAT1, DGAT2, GRIN1 | SMN1; SMN2 4140/4885FPR2 1900/4885KDM4E 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.